Healthcare & Pharmaceutical Market Research in Poland

BioNixus is a leading healthcare market research company in Poland, delivering bioethics-committee-compliant HCP surveys, KOL mapping, and payer landscape research aligned with URPL, AOTMiT, and NFZ requirements. BioNixus combines primary research depth with physician access across major Polish public and university clinical hospitals and specialist community networks — the largest healthcare market in Central and Eastern Europe.

A healthcare market research company in Poland designs and executes studies covering physician prescribing behaviour, NFZ payer and reimbursement access dynamics, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the Polish market.

Poland operates a single public payer, the National Health Fund (NFZ), within an EU member-state regulatory environment. URPL marketing authorisation does not guarantee market access — commercial outcomes depend on AOTMiT health technology assessments, Ministry of Health reimbursement decisions published in the periodic reimbursement list (obwieszczenie refundacyjne), and negotiated risk-sharing schemes (RSS), each with distinct evidence requirements and timelines. Public and university clinical hospital procurement adds further strategic complexity for hospital-administered medicines.

BioNixus covers oncology, immunology and biologics (including biosimilar adoption under tender-driven hospital purchasing), cardiovascular, diabetes and metabolic (including GLP-1), rare disease (drug programmes / programy lekowe), respiratory, infectious disease, neurology, medical devices, and consumer health across the Polish market.

Yes. BioNixus maintains physician and specialist networks across major Polish academic centres including the Medical University of Warsaw, Jagiellonian University Medical College, the Maria Sklodowska-Curie National Research Institute of Oncology, and Poznań University of Medical Sciences. For scarce specialties such as oncology or rare disease, we recruit through Polish oncology centre networks and rare disease specialist directories.

Focused HCP surveys complete in 3–4 weeks. Full mixed-method programmes including NFZ and AOTMiT-oriented payer depth interviews and advisory board modules typically run 6–10 weeks depending on therapy area, bioethics committee review requirements, and respondent scarcity. Oncology and rare disease KOL programmes with multi-centre recruitment across academic clinical hospitals may require extended planning timelines.

Yes. BioNixus designs and executes Polish patient research in compliance with GDPR/RODO data protection standards and bioethics committee (komisja bioetyczna) research ethics requirements. All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling consistent with EU and Polish privacy legislation.

Yes. Polish modules can run with comparable cells in the USA, UK, EU5 (Germany, France, Italy, Spain), Brazil, Saudi Arabia, and UAE — using consistent instruments for global portfolio committees managing multi-market access strategy from one research partner.